全文获取类型
收费全文 | 3552篇 |
免费 | 385篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 54篇 |
妇产科学 | 42篇 |
基础医学 | 506篇 |
口腔科学 | 135篇 |
临床医学 | 315篇 |
内科学 | 704篇 |
皮肤病学 | 74篇 |
神经病学 | 235篇 |
特种医学 | 102篇 |
外科学 | 572篇 |
综合类 | 176篇 |
一般理论 | 2篇 |
预防医学 | 216篇 |
眼科学 | 207篇 |
药学 | 218篇 |
中国医学 | 8篇 |
肿瘤学 | 344篇 |
出版年
2023年 | 35篇 |
2022年 | 21篇 |
2021年 | 132篇 |
2020年 | 95篇 |
2019年 | 105篇 |
2018年 | 173篇 |
2017年 | 126篇 |
2016年 | 121篇 |
2015年 | 119篇 |
2014年 | 165篇 |
2013年 | 201篇 |
2012年 | 269篇 |
2011年 | 282篇 |
2010年 | 154篇 |
2009年 | 127篇 |
2008年 | 210篇 |
2007年 | 194篇 |
2006年 | 186篇 |
2005年 | 160篇 |
2004年 | 159篇 |
2003年 | 128篇 |
2002年 | 111篇 |
2001年 | 83篇 |
2000年 | 84篇 |
1999年 | 57篇 |
1998年 | 24篇 |
1997年 | 19篇 |
1996年 | 16篇 |
1995年 | 17篇 |
1994年 | 11篇 |
1993年 | 22篇 |
1992年 | 27篇 |
1991年 | 32篇 |
1990年 | 25篇 |
1989年 | 19篇 |
1988年 | 31篇 |
1987年 | 22篇 |
1986年 | 17篇 |
1985年 | 22篇 |
1984年 | 11篇 |
1983年 | 21篇 |
1980年 | 8篇 |
1979年 | 16篇 |
1977年 | 10篇 |
1976年 | 8篇 |
1975年 | 10篇 |
1972年 | 7篇 |
1971年 | 9篇 |
1970年 | 6篇 |
1969年 | 6篇 |
排序方式: 共有3955条查询结果,搜索用时 62 毫秒
1.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
2.
3.
4.
5.
6.
7.
The mechanism of action of C-reactive protein (CRP) in protecting mice against lethal Streptococcus pneumoniae infection is unknown. The involvement of the phosphocholine (PCh)-binding property of CRP in its antipneumococcal function previously has been explored twice, with conflicting results. In this study, using three different intravenous sepsis mouse models, we investigated the role of the PCh-binding property of CRP by employing a CRP mutant incapable of binding to PCh. The ability of wild-type CRP to protect mice against infection was found to differ in the three models; the protective ability of wild-type CRP decreased when the severity of infection was increased, as determined by measuring mortality and bacteremia. In the first animal model, in which we used 25 μg of CRP and 107 CFU of pneumococci, both wild-type and mutant CRP protected mice against infection, suggesting that the protection was independent of the PCh-binding activity of CRP. In the second model, in which we used 25 μg of CRP and 5 × 107 CFU of pneumococci, mutant CRP was not protective while wild-type CRP was, suggesting that the protection was dependent on the PCh-binding activity of CRP. In the third model, in which we used 150 μg of CRP and 107 CFU of pneumococci, mutant CRP was as protective as wild-type CRP, again indicating that the protection was independent of the PCh-binding activity of CRP. We conclude that both PCh-dependent and PCh-independent mechanisms are involved in the CRP-mediated decrease in bacteremia and the resulting protection of mice against pneumococcal infection. 相似文献
8.
9.
Peng Shi Ana Chee Weijun Liu Po-Hsin Chou Jun Zhu Howard S. An 《The spine journal》2019,19(1):171-181